Barclays Maintains Overweight on Insmed, Raises Price Target to $237

Barclays analyst Eliana Merle has maintained an Overweight rating on Insmed (NASDAQ: INSM) and raised the price target from $231 to $237. This adjustment reflects a positive outlook for the company.